Printable View
Hi,
I recently had a look at VHT, kiwi health software company, after personal life event.
They released their results for the FY. I bought a bit for a long term run.
What do you guys think about it?
- SaaS company producing different software and an AI algorithm to calculate breast density and risks
- they bought CRA in January, a company that is more into genetic, still in the breast industry
- they hired people from GE With extensive experience to lead their sales
Cheers
CEO Ralph Highnam will be interviewed during Sharesies event "Lunch money". I will follow it, but the video will be uploaded on Youtube after.
And VHT released a video for investor about their Q4 result on their website, really interesting as well.
Quick update from their financial report for FY 2020-2021. Their results look good. still loosing money but they are improving. Hopefully in 1-2 years, they will start making profits!
Highlights:
• Record revenue from customer contracts up 57% to NZ$19.7M
• Subscription revenue up 99% to NZ$18.1M
• Gross margin up to over 91%, from 86% in FY20
• Net loss for the year after tax improved 14% to NZ$17.5M
• Normalised non-GAAP EBITDA1 improved 21% to -NZ$12.4M
• Volpara expects revenue in FY22 of approx. NZ$25.0M to NZ$26.0M
Quick update from their financial report for FY 2020-2021. Their results look good. still loosing money but they are improving. Hopefully in 1-2 years, they will start making profits!
Highlights:
• Record revenue from customer contracts up 57% to NZ$19.7M
• Subscription revenue up 99% to NZ$18.1M
• Gross margin up to over 91%, from 86% in FY20
• Net loss for the year after tax improved 14% to NZ$17.5M
• Normalised non-GAAP EBITDA1 improved 21% to -NZ$12.4M
• Volpara expects revenue in FY22 of approx. NZ$25.0M to NZ$26.0M